Abstract:BACKGROUND: People living with HIV (PLHIV) on antiretroviral therapy (ART) exhibit persistent immune dysregulation and microbial dysbiosis, leading to the development of cardiovascular diseases (CVD). We initially compared plasma proteomic profiles between 205 PLHIV and 120 healthy controls (HCs) and validated the results in an independent cohort of 639 PLHIV and 99 HCs. Differentially expressed proteins (DEPs) were then associated to microbiome data. Finally, we assessed which proteins were linked with CVD development in PLHIV.METHOD: Proximity extension assay technology was utilized to measure 1472 plasma proteins. Markers of systemic inflammation (CRP, D-Dimer, IL6, sCD14, and sCD163) and microbial translocation (IFABP) were measured by ELISA, and gut bacterial species were identified using shotgun metagenomic sequencing. Baseline CVD data were available for all PLHIV, and 205 PLHIV were recorded for the development of CVD during a 5-year follow-up.RESULTS: PLHIV on ART displayed systemic dysregulation of protein concentrations compared to HCs. Most of the DEPs originated from the intestine and lymphoid tissues, while they enriched in immune- and lipid metabolism-related pathways. Furthermore, we observed that DEPs originating from the intestine were associated with specific gut bacterial species. Finally, we identified upregulated proteins in PLHIV (GDF15, PLAUR, RELT, NEFL, COL6A3, and EDA2R), unlike most markers of systemic inflammation, associated with the presence and risk of developing CVD in 5-year follow-up.CONCLUSIONS: Our findings suggest a systemic dysregulation of protein concentrations in PLHIV, of which some proteins were associated with CVD development. Most of DEPs originated from the gut and were related to specific gut bacterial species.TRIAL REGISTRATION: Cohorts included in this study are part of the Human Functional Genomics Project (HFGP) (www.humanfunctionalgenomics.org). The 2000HIV Human Functional Genomics Partnership Program is registered at ClinicalTrials.gov: (ID: NCT03994835).FUNDING: The 200HIV and 2000HIV studies are supported by the AIDS-fonds (#P-29001, Netherlands) and a ViiV healthcare grant (A18-1052), respectively; The ViiV healthcare grant was awarded to A.V., M.G.N., L.A.B.J., and Q.d.M; The Spinoza Prize (NWO SPI94-212) and ERC Advanced grant (no. 833247) were awarded to M.G.N; The Indonesia Endowment Fund for Education (LPDP) given by the Ministry of Finance of the Republic of Indonesia was awarded to N.V.

Estimation of the angle of arrival and the angular spread of a diffuse source in azimuth and sight

Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV

Impact of Chronic HIV Infection on Acute Immune Responses to SARS-CoV-2

Characterization of proinflammatory cytokines profile during acute SARS-CoV-2 infection in people with human immunodeficiency virus

Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus

The welfare state: a eugenic appraisal.

Epidemiological, Virological and Serological Features of Coronavirus Disease 2019 (COVID-19) Cases in People Living with Human Immunodeficiency Virus in Wuhan: A Population-based Cohort Study

[Flavonoid glycosides from leaves of Turpinia arguta and their anti-inflammatory activity].

Relationship of exposure to human T lymphotropic virus and T helper cells in homosexual men.

Deep dissection of the antiviral immune profile of patients with COVID-19

Long-term symptoms after SARS-CoV-2 infection in a cohort of people living with HIV

Evaluation of immune status and selected sirtuins in people living with HIV after fully vaccinating for COVID-19

Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV

Targeted plasma proteomics reveals upregulation of distinct inflammatory pathways in people living with HIV

Associations between post-acute sequelae of SARS-CoV-2, COVID-19 vaccination and HIV infection: a United States cohort study

SARS-CoV-2 Humoral and Cellular Immune Responses in People Living with HIV

The Impact of HIV on B Cell Compartment and Its Implications for COVID-19 Vaccinations in People with HIV

Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study

High-throughput proteomic analysis reveals systemic dysregulation in virally suppressed people living with HIV

Are persons living with diagnosed HIV capable of mounting a strong inflammatory response to the new coronavirus?

Plasma Virome of HIV-infected Subjects on Suppressive Antiretroviral Therapy Reveals Association of Differentially Abundant Viruses with Distinct T-cell Phenotypes and Inflammation